This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Lifshitz Law Firm Announces Investigation Of Chemed Corporation, Overhill Farms, Inc., Theragenics Corporation, And Websense, Inc.

NEW YORK, May 22, 2013 /PRNewswire/ --

Chemed Corporation

Lifshitz Law Firm announces that it is investigating potential claims against the board of Chemed Corporation ("Chemed" or the "Company") (CHE).  On May 2, 2013, the government filed a False Claims Act complaint against the Company and certain of its hospice-related subsidiaries alleging that, since at least 2002, Vitas, and since 2004, the Company, submitted or caused the submission of false claims to the Medicare program by (a) billing Medicare for unnecessary crisis care services, and (b) admitting patients who were not eligible for the Medicare hospice benefit.  The firm is investigating legal claims against the officers and Board of Directors of Chemed.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Overhill Farms, Inc.

Lifshitz Law Firm announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Overhill Farms, Inc. ("Overhill Farms" or the "Company") (OFI) to Bellisio Foods, Inc. in a cash transaction valued at approximately $80.9 million or $5.00 per share in cash.

Lifshitz Law Firm's investigation is focused on whether the proposed deal provides adequate value to the Company's shareholders.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Theragenics Corporation

Lifshitz Law Firm announces an investigation into possible breaches of fiduciary duty in connection with the receipt of a proposal from Juniper Investment Company, LLC ("Juniper") to acquire all of the Theragenics Corporation ("Theragenics" or the "Company") (TGX) outstanding common stock for $2.25 to $2.30 per share in cash.  The Company has entered into an agreement ("Letter Agreement") dated May 12, 2013 to deal and negotiate exclusively with Juniper through June 11, 2013 regarding a merger transaction.

Lifshitz Law Firm's investigation is focused on whether the Board of Directors of the Company is acting in the Company's shareholders' best interests in connection with the sale process.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs